24/7 Market News Snapshot 07 May, 2025 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)

May 7, 2025

DENVER, Colo., 07 May, 2025 (www.247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) has recently demonstrated notable progress in pre-market trading, with shares priced at $1.903, reflecting a robust 10.64% increase from the previous closing price of $1.720. The heightened trading volume of 3.77 million shares indicates a strong investor interest, potentially fueled by positive developments related to the company’s clinical trials. A detailed analysis of the stock’s resistance levels and volume patterns is recommended as sustained buying activity may lead to further gains in the coming sessions.

In a significant development, Phio Pharmaceuticals announced promising results from its Phase 1b clinical trial evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma (cSCC) and other skin cancers. The trial has yielded a complete pathologic response, showcasing tumor clearance in two out of three patients treated within the third dose cohort. This milestone signifies a crucial advancement in Phio’s clinical program, illustrating the potential of PH-762 as a non-surgical treatment alternative for cSCC patients, which is particularly relevant given the increasing incidence of skin cancers.

Additionally, early cohorts have shown four out of nine patients achieving a complete pathologic response, bolstering the therapeutic promise of this innovative treatment. Robert Bitterman, President and CEO of Phio Pharmaceuticals, emphasized that these results represent a pioneering advancement in dermatologic oncology, catering to a critical market demand.

The ongoing trial, currently encompassing ten patients, has been well tolerated without any reported dose-limiting toxicities. As patient enrollment for the fourth cohort progresses, the company anticipates completing this phase by the third quarter of 2025. Mary Spellman, the Acting Chief Medical Officer, underscores that the continued positive pathologic responses reinforce the potential benefits of this immunotherapy, supporting future investigations into PH-762’s efficacy and safety in treating skin cancers.

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.